Advances of Src kinase family and paclitaxel resistance
	    		
		   		
		   			
		   		
	    	
    	 
    	10.11665/j.issn.1000-5048.20170401
   		
        
        	
        		- VernacularTitle:Src激酶家族与紫杉醇耐药相关性的研究进展
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Lu LU
			        		
			        		;
		        		
		        		
		        		
			        		Qinglong GUO
			        		
			        		;
		        		
		        		
		        		
			        		Li ZHAO
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		Src kinase family;
			        		
			        		
			        		
				        		paclitaxel;
			        		
			        		
			        		
				        		cancer resistance;
			        		
			        		
			        		
				        		advances
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			Journal of China Pharmaceutical University
	            		
	            		 2017;48(4):377-383
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	Src family kinase (SFK) highly expresses in many types of cancers,broadly adjusting their malignant behaviors.Paclitaxel is a widely used chemical agent.However,because of constant resistance,the effect of paclitaxel has been greatly attenuated.The present review summaries the recent research progress of the structure and adjustment of SFK and the molecular mechanism of paclitaxel resistance,as well as the regulation of SFK on paclitaxel resistance,in order to provide new references and evidences upon the paclitaxel-based tumor therapy.